Key Highlights

  • SHF Holdings (NASDAQ:SHFS) slipped 17.10% to USD 0.0383 amid Opifex Media Merger talks and preferred conversions.
  • RedCloud Holdings (NASDAQ:RCT) fell 14.81% to USD 0.0299 while it contests a Nasdaq delisting determination.
  • 22nd Century Group (NASDAQ:XXII) dropped 8.91% to USD 0.0675 with no announcement identified.
  • Haoxin Holdings (NASDAQ:HXHX) lost 22.42% to USD 0.1831 following a broker order notice.
  • Karyopharm Therapeutics (NASDAQ:KPTI) declined 7.14% to USD 0.1040 after a Chapter 11 filing.

SHF Holdings (NASDAQ:SHFS) (down USD 0.0079, 17.10%): Sliding Further

In pre-market trading on November 3, 2026, SHF Holdings (NASDAQ:SHFS) slipped 17.10% to USD 0.0383. No company announcement dated November 2 or November 3, 2026 was identified. Its close of USD 0.1158 on October 27, 2026 means the shares are down about 66.9% since then (calculated).

An October 26, 2026 announcement described a non-binding term sheet with Opifex Media, in which Opifex holders would own 85% of the combined company before closing financing and an incentive reserve. Preferred conversions produced 23,914,988 new common shares. Nasdaq pushed back the bid price compliance deadline to April 19, 2027.

RedCloud Holdings (NASDAQ:RCT) (down USD 0.0052, 14.81%): Appeal and Share Consolidation Vote

RedCloud Holdings (NASDAQ:RCT) fell 14.81% to USD 0.0299 in pre-market trading on November 3, 2026. No new company announcement dated November 2 or November 3, 2026 was identified, so the drop appears to extend recent pressure.

On October 13, 2026, Nasdaq issued a Staff Delisting Determination, and the company has appealed, a step that keeps the shares trading. Shareholders approved a share consolidation on October 30, 2026, although the filing does not confirm the final ratio or an effective date. Reported cash of about USD 767 thousand sits against a stockholders' Deficit of about USD 20.6 million, leaving little room for error.

22nd Century Group (NASDAQ:XXII) (down USD 0.0066, 8.91%): Dip Following Pinnacle News

22nd Century Group (NASDAQ:XXII) dropped 8.91% to USD 0.0675 in pre-market trading on November 3, 2026. Nothing new dated November 2 or November 3, 2026 was found, and the dip looks like typical trading in a very low priced stock, an inference rather than a confirmed cause.

Preliminary third-quarter Revenue from continuing operations came in at about USD 4.8 million, up from USD 2.9 million in the second quarter, with a net loss of USD 2.6 million. These figures are unaudited and could change. Cash of USD 3.9 million is modest, which keeps financing and dilution in view. Full third-quarter results are expected on or before November 13, 2026.

Haoxin Holdings (NASDAQ:HXHX) (down USD 0.0529, 22.42%): Notice on Broker Orders

In pre-market trading on November 3, 2026, Haoxin Holdings (NASDAQ:HXHX) lost 22.42% to USD 0.1831. A Shareholder update dated November 2, 2026 said some Brokers may require orders to go through a broker representative, which is the probable trigger. The company never tied the notice to the price move, so that link is an inference.

The company stated that it does not set or control brokerage trading policies. It faces a Nasdaq bid-price deadline after a 180-day extension and has said it may consider a reverse stock split. USD 1.2 million in convertible notes, a USD 30 million Equity line and warrants could all bring dilution.

Karyopharm Therapeutics (NASDAQ:KPTI) (down USD 0.0080, 7.14%): Life Following the Chapter 11 Filing

Following a November 2, 2026 announcement, Karyopharm Therapeutics (NASDAQ:KPTI) slid 7.14% to USD 0.1040 in pre-market trading on November 3, 2026. The company filed voluntary Chapter 11 petitions, and existing lenders pledged up to USD 55 million of debtor-in-possession financing, subject to court approval.

The plan calls for a merger with Ayrmid Ltd. and no distribution to common stockholders, and the company expects existing equity to be worth nothing. The 8-K also cites an expected Nasdaq delisting, although none had been confirmed. Extended-hours quotes may differ widely from regular-session trades.

The Current Picture

Every one of these five stocks trades for pennies, yet each slide reflects its own situation. Karyopharm is in Bankruptcy with no expected value for common equity, SHF Holdings is negotiating a merger while dealing with dilution, RedCloud awaits a Hearings Panel decision, Haoxin is under broker order restrictions, and 22nd Century has no identified catalyst. Keep an eye on the consolidation effective date at RedCloud, the bidding procedures at Karyopharm, any definitive agreement at SHF Holdings, and 22nd Century's full results by November 13, 2026.